The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

Francesca Forzano¹, Olga Antonova², Angus Clarke³, Guido de Wert⁴, Sabine Hentze⁵
Yalda Jamshidi⁶, Yves Moreau⁷, Markus Perola⁸, Inga Prokopenko⁹,¹⁰,¹¹, Andrew Read¹²,
Alexandre Reymond¹³, Vigdis Stefansdottir¹⁴, Carla van El¹⁵, Maurizio Genuardi¹⁶,¹⁷
behalf of the Executive Committees and the Public and Professional Policy Committee of the
European Society of Human Genetics

Affiliations and email
¹ Clinical Genetics Department, Guy’s and St Thomas NHS Foundation Trust, London, UK
francesca.forzano@gstt.nhs.uk
² Department of Medical Genetics, Medical University of Sofia, Sofia, Bulgaria
contact.drolgaantonova@gmail.com
³ Institute of Medical Genetics, School of Medicine, Cardiff University, Wales, UK
clarkeaj@cardiff.ac.uk
⁴ Maastricht University, Maastricht, the Netherlands g.dewert@maastrichtuniversity.nl
⁵ Human Genetics, Heidelberg, Germany sabine.hentze@embl.de
⁶ Genetics Research Centre, Molecular and Clinical Sciences Institute, St George's University
of London, UK. vjamshid@sgul.ac.uk
⁷ ESAT-STADIUS, KU Leuven, Belgium moreau@esat.kuleuven.be
⁸ Institute for Molecular Medicine, Helsinki, Finland markus.perola@thl.fi
⁹ Department of Clinical & Experimental Medicine, University of Surrey, Guildford, United
Kingdom i.prokopenko@surrey.ac.uk
¹⁰ UMR 8199 - EGID, Institut Pasteur de Lille, CNRS, University of Lille, F-59000 Lille,
¹¹ France
Abstract

Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation (IFV) as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regards to the selection of individual traits, should take place before any further implementation of the technique in this population.
**Keywords**: Polygenic risk scores; PRS; PGT; PGT-P; IVF; embryo selection.

**Introduction**

Polygenic risk scores (PRSs) are estimates of an individual’s susceptibility to a specific complex trait obtained by aggregating the effects of dozens, thousands, and potentially millions of genetic variants associated with that specific trait into a single figure. Some private companies have begun to market PRS analyses on embryos to prospective parents through the use of *in vitro* fertilisation and pre-implantation genetic testing (PGT; PGT-P) [1,2,3,4]

This practice raises many concerns.

Complex traits are determined by a combination of genes and environment, and PRSs can only capture a part of the genetic component – that which is derived from the cumulative effects of many genetic variants of small individual effect. PRSs themselves should be calculated using their effects from the ethnic group the parents belong to. The estimation of PRSs for children of parents from diverse ethnic origins is not yet possible to determine correctly. For risks to be calculated as accurately as possible, PRSs should be combined with the effects of non-genetic factors from an individual’s life-history such as environment, nutrition, and physical activity. Furthermore, the effects of the genetic factors may interact with each other as well as with changes in lifestyle and clinical risk factors throughout an individual’s life, and these interactions may be difficult to account for when calculating the PRS. The concomitant occurrence of rare genetic variants of major effect, whose presence might be unknown, can influence hugely the calculation of the PRS, thus introducing an additional layer of complexity.
The PRS situation today – uses and limitations

Currently, PRS assessments capture only a fraction of the total estimated heritable component of a trait [5,6], partly because they are determined using only a limited number of polymorphic variants in certain genes. The PRSs are commonly calculated as a weighted sum of the number of disease risk (increasing/decreasing) variants carried by an individual, where the risk variants and their weighting is derived from genome-wide association studies (GWASs) [7,8] may not be the relevant genetic factors but simply located nearby, thus introducing uncertainty in the estimates of effect size associated with individual variants in PRS. The GWASs are typically carried out in populations of defined ancestry (commonly European) and the data extrapolated from those studies might not be valid for populations of different ancestries. As such their general applicability can also be limited.

Importantly, individual variants may increase the risk for one trait, while simultaneously reducing the risk of another. This complexity is often not obvious to individuals who request information about their future risk through PRS, because they are only informed about the risk for a specific trait that they have sought advice for. They are therefore not provided with data about the risks or benefits of another trait influenced by the same variants, which may or may not be known and might also have included those with effects on prenatal development.

Given the many limitations summarised above, PRSs are not used in clinics. However, it seems plausible that, in the near future, some may be introduced into clinical assessment with the aim of improving the identification of at-risk individuals, and treatment for specific conditions.
[9,10]. However, this would not necessarily be translated into implementation for prenatal diagnostics.

In a proper clinical or research setting, an assessment of all potential contributory risks, including genetic and environmental ones, would be undertaken and made available. Outside of this framework, and especially when PRS assessments are provided as direct-to-consumer (DTC) tests, their evaluation of a patient’s risk may be dangerously incomplete and can lead to grave misunderstandings [11,1]. Extrapolating the results from predictive assessments in adult cohorts to use them as a factor for embryo screening would be improper. No clinical research protocol has been performed so far to assess the diagnostic effectiveness of PRSs in embryos. Were these be established, it would take many years to obtain reliable results, given that one might have to wait decades for people to develop, for example, early-onset Alzheimer’s disease.

**The use of PRS in embryo screening and selection**

While it is relatively common for parents to consider any genetic risks they may pass on to their children, this is normally undertaken via the proven practice of carrier screening and genetic testing for inherited mendelian disorders. In these cases, the ability of the test to predict the development of the disease is usually very high. In fact, when a genetic condition has an extremely low penetrance (the proportion of people with a particular genetic variant who exhibit signs and symptoms of a genetic disorder is low), it is very rare that the prospective parents would even consider prenatal or preimplantation testing.

When applied to the selection of embryos for transfer, the PRS will relate to an individual family, and not to a wide population. The intrafamilial variability would be much more limited
than in the wider population, and therefore the PRS would be unlikely to be useful in
determining the choice of one embryo over another, particularly as the number of viable
embryos available is typically very small. Even if a discrete difference exists between two or
more viable embryos suitable for transfer, a particular combination of genetic variants detected
and evaluated would not relate to a definitive diagnosis. Such a set of variants will correspond
at best to a small increase in an individual’s risk, relative to the population’s risk for a complex
trait, if the prediction is based on estimates for an ethnic group (ancestry) corresponding to that
of the parents. Additionally, if the selection were aimed at more than one PRS per embryo, it is
easy to estimate by simple probability that the total number of embryos needed to be examined
in order to find at least one (if any) suitable embryos to transfer would be unrealistic for our
species and would also be unethical.

Overall, adding PRSs to PGT would amount to a form of embryo screening. The criteria to
assess and implement a screening programme would include, among others, the proportionality
principle, according to which ‘the possible benefits of the screening should clearly outweigh its
possible disadvantages’. For the assessment of the proportionality of PRSs in PGT, it is
important to take account of tensions with other parameters, more important for ranking
embryos for transfer. Such parameters include viability scores and implications for the complex
counselling process, especially when the values of professionals and customers for embryo
ranking do not match.

Research on PRSs is not aimed at the development of pre-symptomatic tests in embryos but
rather at the advancement of understanding of disease mechanisms, and the management and
treatment of liveborn individuals, most frequently when they reach their adulthood. For PRS
research, the aim is different, the population is different, the setting is different from what is expected from PGT.

Protecting prospective parents, their offspring, and society

At present, carrying out a PRS test for embryo selection would be premature at best. Prospective parents and the public must be provided with adequate and unbiased information on the risks and limitations of such a practice [12]. It will be vital that a societal debate takes place before any potential application of the technique, and this should be focused on what would be considered acceptable with regards to the selection of individual traits, in particular. Without proper public engagement and oversight, the practice of implementing PRS test for embryo selection could easily lead to discrimination and the stigmatisation of certain conditions.

Further studies are needed to understand which and how polygenic risk estimates for common diseases can be implemented in clinical care. Such research should disentangle the complex interplay between PRSs for a range of conditions and the environment. More studies are needed to understand the biology of normal embryonic and foetal development, as well as its interplay with the intrauterine environment, that is still so elusive.

For the time being, it is important for reasons of justice to assess whether public and individual resources can be better used to improve our knowledge on PRSs and their relationships with the environment in which we live, rather than on the premature application of an inadequately evaluated test to our future children.
Members of the Executive Committees of the ESHG in 2021 were
Maurizio Genuardi (President, Rome, Italy), Borut Peterlin (President-Elect, Ljubljana, Slovenia), Alexandre Reymond (Vice-President, Lausanne, Switzerland), Carla Oliveira (Secretary-General, Porto, Portugal), Karin Writzl (Deputy Secretary-General, Ljubljana, Slovenia), Gunnar Houge (Treasurer, Bergen, Norway)

Members of the Public and Professional Policy Committee of the ESHG in 2021 were
Francesca Forzano (Chair, London, United Kingdom), Angus Clarke (Cardiff, United Kingdom), Christophe Cordier (Lausanne, Switzerland), Guido de Wert (Maastricht, The Netherlands), Sabine Hentze (Heidelberg, DE), Heidi Howard (Uppsala, Sweden), Milan Macek (Prague, Czech Republic), Bela Melegh (Pecs, Hungary), Alvaro Mendes (Porto, Portugal), Yves Moreau (Leuven, Belgium), Markus Perola (Helsinki, Finland), Inga Prokopenko (Guildford, Surrey, United Kingdom), Dragica Radojkovic (Belgrade, Serbia), Emmanuelle Rial-Sebbag (Toulouse, France), Vigdis Stefánsdóttir (Reykjavik, Iceland), Fiona Ulph (Manchester, United Kingdom), Carla van El (Secretary General, Amsterdam, The Netherlands). Observers were: Olga Antonova (Sofia, Bulgaria), Yalda Jamshidi (London, United Kingdom)

Conflict of Interest.
The authors declare to have no conflict of interest.

Funding.
Professor Inga Prokopenko has received funding by: the World Cancer Research Fund (WCRF UK) and World Cancer Research Fund International (2017/1641), the European Union’s Horizon 2020 research and innovation programme (LONGITools, H2020-SC1-2019-
874739), the Ministry of Science and Higher Education of Russian Federation (075-15-2021-595), Agence Nationale de la Recherche (PreciDIAB, ANR-18-IBHU-0001), by the European Union through the “Fonds européen de développement regional” (FEDER), by the “Conseil Régional des Hauts-de-France” (Hauts-de-France Regional Council) and by the “Métropole Européenne de Lille” (MEL, European Metropolis of Lille).

References


